Hyperfine Achieves 500 Scan Milestone for Swoop System in U.S. Hospitals
Hyperfine announced the achievement of scan volume milestones in key hospitals and neurology clinics, demonstrating accelerating clinical utilization and adoption of the Swoop(R) system throughout the United States. The increasing clinical use of the Swoop system is driven by several factors: enhanced clinical utility from improved image quality, growing evidence of its economic value, and expanding adoption across new care settings, including neurology clinics and the emergency department. The most successful Swoop system programs are driven by visionary healthcare leaders who are passionate about addressing the challenges of MRI availability and recognize the clinical and economic value of portable MRI in expanding patient access to imaging. CHRISTUS Mother Frances, one of the first sites to adopt the next-generation Swoop system, crossed the 500-scan milestone in just nine months, driven by integrating the Swoop(R) system into a scalable stroke program. Clinical use of the Swoop system is accelerating in neurology offices, where it has quickly become a valuable extension of the diagnostic workflow since its introduction in mid-2025. Neurology of Central Florida has already exceeded 500 in-office MRI scans, demonstrating how point-of-care imaging enables neurologists to complete diagnostic evaluations within their own practice.
Trade with 70% Backtested Accuracy
Analyst Views on HYPR
About HYPR
About the author

- Clinical Milestone Achieved: Hyperfine's Swoop® system has surpassed 1,000 scans in key hospitals and neurology clinics across the U.S., indicating a significant increase in clinical utilization and adoption, thereby promoting the widespread use of portable MRI in healthcare.
- Significant Economic Benefits: Research from Jefferson Abington Hospital shows that the use of the Swoop® system not only improved patient care but also significantly reduced MRI wait times in the ICU and ED, enhancing hospital operational efficiency and reflecting the economic value of portable MRI.
- Rapid Application Expansion: CHRISTUS Mother Frances Hospital achieved 500 scans in just nine months, demonstrating the successful integration of the Swoop® system into its stroke program, leading to the purchase of additional equipment to enhance emergency patient care and reduce unnecessary admissions and transport costs.
- Optimized Diagnostic Workflow: Neurology of Central Florida has completed over 500 in-office MRI scans, with the introduction of the Swoop® system allowing neurologists to finalize diagnostic evaluations within 24 to 72 hours, significantly shortening patient wait times and improving the timeliness of medical decisions.
- Index Inclusion Expected: Hyperfine (HYPR) is anticipated to join the Russell 2000 and Russell 3000 indexes after the U.S. market closes on June 26, based on a preliminary list published by FTSE Russell on May 22, indicating increased recognition in the capital markets.
- Strategic Progress: CEO Maria Sainz stated that this inclusion reflects advancements in the company's commercial strategy and the adoption of its portable MRI technology, suggesting enhanced growth potential moving forward.
- Strong Financial Performance: In its Q1 2026 earnings report, Hyperfine reported revenue of $3.90 million, exceeding market expectations by $0.37 million, while the GAAP EPS of -$0.09 indicates a solid gross margin of 50%-55%, showcasing robust profitability.
- Future Revenue Targets: Hyperfine has set a revenue target of $20 million to $22 million for 2026, demonstrating confidence in future growth and reflecting its ongoing innovation and market expansion capabilities in the healthcare technology sector.
- Clinical Trial Results: At the 2026 Annual Meeting of the Society for Academic Emergency Medicine, Hyperfine presented results from the PRIME study, demonstrating that portable MRI significantly enhances imaging efficiency in emergency departments by reducing the median time from imaging order to scan start from 7.76 hours to 1.28 hours, a difference of 6.35 hours, highlighting its potential value in urgent situations.
- Critical Pathology Detection: Among completed scans, 18.6% revealed critical pathologies such as acute ischemic stroke and mass lesions, which were successfully detected by portable MRI and confirmed by conventional MRI, underscoring its importance in rapid diagnosis.
- Workflow Optimization: The study indicates that portable MRI can be integrated into emergency department workflows more swiftly, alleviating patient boarding delays associated with waiting for conventional MRI, thereby enhancing overall care efficiency for emergency teams.
- Future Development Potential: Hyperfine's Swoop® system, by providing faster imaging services, may transform emergency medicine, assisting clinicians in accessing actionable imaging information sooner and advancing the field of emergency neuroimaging.
- Significant Revenue Growth: Hyperfine reported Q1 2026 revenue of $3.9 million with a gross margin of 51%, demonstrating effective execution in both growth and cost control, thereby enhancing its competitive position in the market.
- International Expansion Progress: The company obtained CE and UKCA marks for its next-generation Swoop system and DWI Optive AI software, with plans to launch in Europe in Q3, further broadening its international business footprint.
- Increased Product Adoption: The advanced DWI Optive AI software is now implemented in most scanners, with unit sales rising from 6 to 10 compared to the prior year, indicating accelerated penetration in the large customer market.
- Stable Financial Outlook: Management reiterated full-year revenue expectations between $20 million and $22 million, with gross margins projected to remain between 50% and 55%, and cash burn controlled at $26 million to $28 million, reflecting confidence in future performance.
- Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
- Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
- CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
- Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
- Clinical Use Initiated: AIIMS New Delhi, in partnership with Radiosurgery Global India, has begun clinical use of the Hyperfine Swoop® portable MRI system, marking a significant milestone in neurological care that is expected to greatly enhance imaging efficiency for emergency and critically ill patients.
- Significant Technical Advantages: The Swoop® system eliminates the need for dedicated rooms or patient transport, allowing for bedside brain imaging in ICUs and trauma centers, thereby removing the risks associated with traditional MRI transport and improving diagnostic speed and patient outcomes.
- Broad Clinical Impact: This system addresses unmet clinical needs across neurology, trauma care, and critical care, particularly in providing rapid assessment for acute stroke and traumatic brain injury, delivering essential imaging support at critical moments.
- Platform for Research and Innovation: The deployment at AIIMS New Delhi establishes a foundation for clinical research, with plans to document outcomes and advance the adoption of portable MRI in India, enhancing the country's role in the global brain imaging landscape.








